Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Telmisartan on insulin resistance and fatty liver in patients with hypertension
2009-015703-13Phase 4Completed
- Sponsor
- Klinikum Chemnitz
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of telmisartan in hypertension (HTN), insulin resistance (IR) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Klinikum Chemnitz. Primary endpoints: Normalization or increase of ISI-Matsuda at 6 months and Normalization or increase of ISI-Matsuda at 3 months. Started Nov 2009; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)insulin resistance (IR)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2009-015703-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015703-13.